NEW YORK, Nov. 11, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) (ISIN: US0153511094). Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether Alexion and certain of its officers and/or directors have violated the federal securities laws.
On November 4, 2016, Alexion abruptly cancelled an appearance at the Credit Suisse Healthcare Conference, scheduled to run November 6-8, 2016. Also on November 4, 2016, Alexion failed to file by market close its quarterly report on Form 10-Q with the SEC within its historical two-day window following an earnings announcement on October 27, 2016. On this news, Alexion stock fell $8.95, or 6.94%, to close at $120.05 on November 7, 2016, the next trading day.
On November 9, 2016, Alexion revealed that its board of directors is investigating allegations of improper sales practices tied to its top-selling drug Soliris.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
SOURCE Pomerantz LLP